Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,680.14
    -1,444.72 (-2.88%)
     
  • CMC Crypto 200

    1,261.69
    -96.32 (-7.09%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

3 Reasons to Buy the Dip With DexCom Stock

The first reason to buy DexCom stock is that it's slumping as a result of short-term issues that won't have much of an impact once they're resolved. Its latest continuous glucose monitor (CGM) in development for diabetes management, the G7, hit a snag in its approval process with regulators at the Food and Drug Administration (FDA). Then, when the G7 ultimately launches in the U.S., DexCom's revenue growth will likely pick up once more, and its stock price should follow.